Ash 2021 – Sangamo and Sanofi enter the sickle cell gene editing fray
SAR445136 could take on Crispr and Vertex’s CTX001, but plenty of other groups have the same idea.
Intellia proves its point
The first clinical evidence for in vivo gene editing, and a surge in valuation, is to be celebrated. But there is much more to do.
For a quick exit, head to the stock market
Venture-backed companies are floating earlier, but time to takeout stays stubbornly steady.
Covid-19 stalls biotech flotations
Several young drug developers managed to float in the first quarter, but new issues dried up in March when coronavirus infected the markets. Is the game back on?
Venture funding slowdown continues in first quarter of 2019
Venture funding drops again, but there’s no need to panic yet.
The venture money keeps flowing for biopharma
Private drug developers raised a record $8.5bn in the first half of 2018, amid a surge in mega rounds.
